Ongoing phase III program : FRESH and REFRESH studies
Clinical Development of First-in-Class firibastat, the first drug candidate in the BAPAI class, for the treatment of high blood pressure
Ongoing phase II study:
Quorum
Development of firibastat product for the treatment of heart failure
Preclinical stage
(proof of concept on animals)
Optimization of BAPAI products and development of a “Best-in-Class” product
Development of therapeutic combinations involving a BAPAI with another antihypertensive drug